Imugene Valuation

Is IMU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMU's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMU?

Other financial metrics that can be useful for relative valuation.

IMU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20x
Enterprise Value/EBITDA-3.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IMU's PS Ratio compare to its peers?

The above table shows the PS ratio for IMU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.6x
CUV Clinuvel Pharmaceuticals
9.6x22.5%AU$783.7m
DXB Dimerix
29.6xn/aAU$269.6m
ARX Aroa Biosurgery
3.4x21.7%AU$213.4m
ACW Actinogen Medical
39.9x24.0%AU$191.3m
IMU Imugene
28.8x55.2%AU$433.6m

Price-To-Sales vs Peers: IMU is expensive based on its Price-To-Sales Ratio (28.8x) compared to the peer average (20.6x).


Price to Earnings Ratio vs Industry

How does IMU's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a15.2%
n/an/an/a
No more companies

Price-To-Sales vs Industry: IMU is expensive based on its Price-To-Sales Ratio (28.8x) compared to the Australian Biotechs industry average (10.2x).


Price to Sales Ratio vs Fair Ratio

What is IMU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio28.8x
Fair PS Ratio48x

Price-To-Sales vs Fair Ratio: IMU is good value based on its Price-To-Sales Ratio (28.8x) compared to the estimated Fair Price-To-Sales Ratio (48x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.059
AU$0.35
+498.9%
41.5%AU$0.49AU$0.15n/a3
Jul ’25AU$0.055
AU$0.35
+542.4%
41.5%AU$0.49AU$0.15n/a3
Jun ’25AU$0.067
AU$0.35
+427.4%
41.5%AU$0.49AU$0.15n/a3
May ’25AU$0.084
AU$0.35
+320.6%
41.5%AU$0.49AU$0.15n/a3
Apr ’25AU$0.10
AU$0.34
+220.6%
50.4%AU$0.49AU$0.10n/a3
Mar ’25AU$0.12
AU$0.35
+191.7%
50.6%AU$0.49AU$0.10n/a3
Feb ’25AU$0.10
AU$0.35
+250.0%
50.6%AU$0.49AU$0.10n/a3
Jan ’25AU$0.11
AU$0.35
+218.2%
50.6%AU$0.49AU$0.10n/a3
Dec ’24AU$0.10
AU$0.35
+250.0%
50.6%AU$0.49AU$0.10n/a3
Nov ’24AU$0.042
AU$0.37
+773.0%
52.2%AU$0.54AU$0.10n/a3
Oct ’24AU$0.046
AU$0.42
+813.0%
35.5%AU$0.54AU$0.21n/a3
Sep ’24AU$0.066
AU$0.49
+642.4%
36.7%AU$0.71AU$0.21n/a4
Aug ’24AU$0.10
AU$0.47
+370.0%
37.8%AU$0.71AU$0.21n/a4
Jul ’24AU$0.091
AU$0.47
+416.5%
37.8%AU$0.71AU$0.21AU$0.0554
Jun ’24AU$0.10
AU$0.47
+370.0%
37.8%AU$0.71AU$0.21AU$0.0674
May ’24AU$0.13
AU$0.51
+288.5%
25.8%AU$0.71AU$0.35AU$0.0844
Apr ’24AU$0.13
AU$0.51
+288.5%
25.8%AU$0.71AU$0.35AU$0.104
Mar ’24AU$0.13
AU$0.51
+288.5%
25.8%AU$0.71AU$0.35AU$0.124
Feb ’24AU$0.14
AU$0.51
+260.7%
25.8%AU$0.71AU$0.35AU$0.104
Jan ’24AU$0.14
AU$0.51
+248.3%
25.8%AU$0.71AU$0.35AU$0.114
Dec ’23AU$0.19
AU$0.51
+165.8%
25.8%AU$0.71AU$0.35AU$0.104
Nov ’23AU$0.20
AU$0.51
+162.8%
24.6%AU$0.71AU$0.36AU$0.0424
Oct ’23AU$0.18
AU$0.51
+184.7%
24.6%AU$0.71AU$0.36AU$0.0464
Sep ’23AU$0.25
AU$0.55
+121.3%
20.4%AU$0.71AU$0.45AU$0.0663
Aug ’23AU$0.23
AU$0.55
+145.9%
20.4%AU$0.71AU$0.45AU$0.103
Jul ’23AU$0.20
AU$0.55
+183.8%
20.4%AU$0.71AU$0.45AU$0.0913

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.